AbCellera Closes Series A led by DCVC Bio

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced today that it has closed its Series A financing led by DCVC Bio, a Silicon Valley venture capital fund focused on deep technology ventures that lie at the nexus of artificial intelligence and biotechnology. AbCellera will use the USD $10 million financing to accelerate the growth of their therapeutic antibody discovery business, including investments to build capacity and integration of advanced technological capabilities spanning computation, protein engineering, and immune repertoire profiling. "With this financing, we will double-down on our partnership business that has enjoyed profitable, triple-digit growth over the past 3 years. In DCVC Bio, we have found the ideal funding partner to help us accelerate the success of our full-stack antibody discovery engine, one that integrates artificial intelligence with industry-leading microfluidic screening technology," said Carl Hansen, CEO of AbCellera. AbCellera's high-throughput single B cell screening platform and repertoire sequencing technologies enable discovery of large multidimensional data sets of valuable antibody sequences.